Understanding Cystinuria
An inherited amino acid transport disorder that causes recurrent cystine kidney stones, often starting in childhood, and requires lifelong management to protect kidney function.
- Inherited Transport Disorder
- Lifelong Stone Prevention
- Specialist Urology & Genetics Input
- Emerging Pharmacologic Options
- Estimated Prevalence
- ~1 in 7,000 births
- Typical Onset
- Childhood to young adulthood
- Inheritance Pattern
- Autosomal recessive
- Advanced Options
- Tiopronin, Captopril, Gene-informed Counseling
Condition Overview
Cystinuria is an inherited disorder of amino acid transport in which the kidneys fail to properly reabsorb cystine and other dibasic amino acids from the urine. The resulting high urinary cystine concentration leads to the formation of cystine stones, which are poorly soluble and tend to recur throughout life.
The condition affects people of all ages but often first presents in childhood or early adulthood with kidney stone episodes. Because cystine stones do not respond to the same dietary or medical strategies as the more common calcium-based stones, accurate diagnosis is essential to guide effective long-term management.
With consistent hydration, urinary alkalinization, and in some cases specific medications, many people with cystinuria can significantly reduce stone recurrence and protect long-term kidney function.
Genetic Subtypes
Cystinuria is classified by the underlying gene defect, which can influence inheritance pattern and, to some degree, disease severity.
Symptoms and Signs
Symptoms of cystinuria are largely driven by recurrent stone formation and its complications.
Causes and Risk Factors
Cystinuria is caused by mutations affecting amino acid transporters in the proximal renal tubule and intestine.
Diagnosis and Investigations
Diagnosis combines stone composition analysis, urine testing, and in some cases genetic confirmation.
Disease Severity Classification
Cystinuria is not staged like a malignancy, but clinicians often classify severity by stone burden and frequency to guide treatment intensity.
Standard Treatment Options
Management focuses on reducing cystine concentration and solubility in the urine, alongside treating existing stones.
Advanced and Emerging Treatment Options
Research continues into therapies that more effectively reduce cystine solubility or address the underlying transport defect.
Pharmacologic
Tiopronin / Alpha-mercaptopropionylglycine
A thiol-binding agent used when conservative measures fail to adequately control stone recurrence.
Pharmacologic
ACE inhibitor-based thiol agents (e.g. captopril)
Some ACE inhibitors with a thiol group have been used off-label to reduce cystine stone formation.
Precision Medicine
Genetic counseling and carrier testing
Supports family planning and helps identify at-risk relatives for early monitoring.
Investigational
Novel crystallization inhibitors
Compounds designed to interfere with cystine crystal growth are under early-stage investigation.
Biomarkers and Monitoring Parameters
Cystinuria management relies on biochemical monitoring rather than tumor-style biomarkers, but several parameters guide treatment intensity.
When a Second Opinion May Be Important
Several scenarios in cystinuria management benefit from specialist nephrology or urology review.
Clinical Trials and Research
Prognosis and Key Outcome Factors
With consistent management, most people with cystinuria can substantially reduce stone recurrence and preserve kidney function over a normal lifespan, though the condition requires lifelong vigilance.
Supportive Care and Living With Cystinuria
Living with cystinuria involves daily habits and ongoing monitoring to minimize stone recurrence and protect kidney health.
How CancerFax Helps You Explore Treatment Options
CancerFax can help you organize your stone analysis and imaging reports, coordinate a second opinion with a specialist nephrologist or urologist, and connect you with centers experienced in long-term cystinuria management.
Get a free case reviewFrequently Asked Questions
Cystinuria is an inherited disorder in which the kidneys cannot properly reabsorb cystine, leading to recurrent cystine kidney stones throughout life.
No. Cystine stones have a different chemical composition than the more common calcium-based stones and require specific prevention strategies, such as alkalinization and, in some cases, thiol-binding medications.
Diagnosis typically involves stone composition analysis, urine cystine quantification, and sometimes genetic testing of the SLC3A1 and SLC7A9 genes.
There is currently no cure, but cystinuria can usually be well controlled with hydration, urinary alkalinization, dietary changes, and medication when needed.
Cystinuria is typically inherited in an autosomal recessive pattern, meaning both parents usually carry a gene variant. Genetic counseling can clarify individual family risk.
Yes. Reducing sodium and animal protein intake, alongside high fluid intake, can meaningfully lower urinary cystine levels in many patients.
Untreated recurrent stones can cause infections, obstruction, and progressive kidney damage over time, making consistent management important.
Researchers are studying improved crystallization inhibitors and better-tolerated medications, though hydration and alkalinization remain the foundation of care today.
Children may require adjusted dosing and closer growth and kidney function monitoring compared with adults, so pediatric specialist input is valuable.
Yes. CancerFax can help you organize and review your medical reports, facilitate a second opinion with an experienced nephrologist or urologist, and coordinate access to specialist centers for ongoing cystinuria management.
Get Support Managing Cystinuria
Connect with specialists experienced in cystine stone prevention and long-term kidney health management.